Cure My Disease

Don't miss your cure!

 Log in / Sign up

New device could help heart failure patients avoid repeat hospital stays

NCT ID NCT07173426

Disease control Sponsor: Mid and South Essex NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial tests whether a quick, painless electrical test called bioimpedance analysis (BIA) can help doctors better manage fluid levels in patients hospitalized with worsening heart failure. 255 participants will be randomly assigned to receive either BIA-guided treatment or standard care. The goal is to see if BIA reduces the need for extra diuretics or rehospitalization within 90 days after discharge.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bioimpedance analysis device
What this could lead to
If it works, this could provide a simple bedside tool to guide diuretic treatment, potentially reducing hospital readmissions and improving fluid management for heart failure patients.
What could go wrong
This is a relatively small, early-stage trial (255 participants) testing a device, not a drug. The benefit may be modest, and results may not apply to all heart failure patients, especially those with severe illness or kidney problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 255 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \>18 years 2. Patients with hospitalised with a decompensated episode of Heart Failure regardless of Ejection Fraction 3. Able and willing to consent. Exclusion Criteria: 1. Patients on a palliative care pathway and/or estimated life expectancy \<3 months 2. Patients admitted to ITU/ on intensive care support. 3. Patients currently taking part in any trials investigating new heart failure drug or interventional treatment. 4. Patients requiring Renal Replacement Therapy. 5. Patients unable or unwilling to give consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Decompensated heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Decompensated heart failure Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Basildon University Hospital

    RECRUITING

    Basildon, Essex, SS16 5NL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.